{"entity":{"id":"nct05165433","kind":"trial","name":"Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)","aka":[],"tldr":"A phase 1 trial of NG-350A run by Akamis Bio, completed.","summary":"Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY) is a phase 1 interventional study registered as NCT05165433 by Akamis Bio, with 14 participants enrolled, started 2022-04-13, primary completion reached 2025-08-29. Conditions recorded: Epithelial Tumor, Metastatic Cancer. Interventions recorded: NG-350A plus Pembrolizumab.","status":"completed","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT05165433","url":"https://clinicaltrials.gov/study/NCT05165433"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["ng-350a"],"companies":["akamis-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05165433","phase":"1","setting":"A Multicentre, Open-label, Non-randomized, Phase 1a/1b Study of NG-350A, a Tumour-selective Anti-CD40-expressing Adenoviral Vector, in Combination With Pembrolizumab in Patients With Metastatic or Advanced Epithelial Tumours","sponsor":"Akamis Bio","enrolled":14,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05165433/","neighbours":{"drug":[{"id":"ng-350a","kind":"drug","name":"NG-350A","route":"/drugs/ng-350a/"}],"company":[{"id":"akamis-bio","kind":"company","name":"Akamis Bio","route":"/companies/akamis-bio/"}]}}